
Olemedia
Greenwich Life Sciences (NASDAQ:GLSI) is trading higher on Wednesday after the immunotherapy developer provided an update on the commercial manufacturing of its lead candidate GP2, which is currently in a late-stage trial called FLAMINGO-01 for breast cancer. breast.
Noting that data on commercial manufacturing also